View More Recent Stories

Mar 4, 2025 05:46AM BTIG Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Mar 4, 2025 04:55AM Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Goldman Sachs
Mar 3, 2025 01:06PM Syndax Pharmaceuticals (SNDX) PT Lowered to $29 at B.Riley
Feb 17, 2025 05:41PM Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Jan 6, 2025 12:31PM Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Dec 28, 2024 01:38PM Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Nov 19, 2024 11:00AM JPM just added these stocks to its Analyst Focus List - giving one 148% upside
Nov 18, 2024 07:59AM TD Cowen Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Nov 18, 2024 06:54AM Syndax Pharmaceuticals (SNDX) PT Raised to $51 at H.C. Wainwright
Nov 13, 2024 07:20AM Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank
Nov 13, 2024 06:53AM Syndax Pharmaceuticals (SNDX) PT Raised to $49 at H.C. Wainwright
Nov 13, 2024 05:46AM Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Goldman Sachs
Nov 12, 2024 07:06AM Syndax Pharmaceuticals (SNDX) Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Nov 6, 2024 06:48AM Syndax Pharmaceuticals (SNDX) PT Raised to $47 at H.C. Wainwright
Nov 5, 2024 04:04PM Syndax Pharmaceuticals (SNDX) Tops Q3 EPS by 9c, provides guidance
Nov 4, 2024 04:02PM Syndax Pharmaceuticals (SNDX) and Royalty Pharma (RPRX) Enter $350M Royalty Funding Agreement for Niktimvo
Oct 24, 2024 03:22AM UBS Starts Syndax Pharmaceuticals (SNDX) at Buy
Oct 9, 2024 06:22AM B.Riley Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Sep 18, 2024 05:17PM Syndax (SNDX) and Incyte (INCY) Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo
Aug 16, 2024 06:42AM Syndax Pharmaceuticals (SNDX) PT Raised to $45 at H.C. Wainwright
Aug 15, 2024 10:35AM TD Cowen Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Aug 15, 2024 09:27AM Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
Aug 15, 2024 06:25AM Syndax Pharmaceuticals (SNDX) PT Raised to $31 at BofA Securities
Aug 12, 2024 07:02AM Syndax Pharmaceuticals (SNDX) Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
Aug 1, 2024 04:49PM Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 11c
Jul 30, 2024 05:19AM Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities
Jul 29, 2024 10:53AM Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at Stifel
Jul 29, 2024 07:01AM Syndax Pharmaceuticals (SNDX) Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Jun 28, 2024 05:08AM Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy
Jun 26, 2024 02:59AM Syndax Pharmaceuticals (SNDX) PT Raised to $42 at Stifel
Jun 14, 2024 07:00AM Syndax Pharmaceuticals (SNDX) Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib
View More Recent Stories